The transcription factor Ets-1 regulates the expression of several angiogenic and extracellular matrix remodeling factors, and might be implicated in disease progression of breast cancer. In the present study, the prognostic value of Ets-1 expression was assessed by quantitative realtime fluorescence RT -PCR in 123 sporadic primary breast cancer samples of patients with a median followup time of 62 months. Ets-1 expression levels correlated significantly with VEGF and PAI-1 in the same tissue. In univariate (P=0.0011) and multivariate (P=0.005) analyses, Ets-1 expression showed significant prognostic value for relapse-free survival. Ets-1 is a strong, independent predictor of poor prognosis in breast cancer. This seems -at least in part -to be attributable to its role in transcriptional regulation of factors involved in angiogenesis (VEGF), and extracellular matrix remodeling (PAI-1).
All members of the E26 transformation-specific (Ets) family of transcription factors contain a conserved winged helix -turn -helix DNA binding domain, regulating gene expression by binding to so-called Ets-binding sequences (EBS) found in promoter/ enhancer regions of their target genes (Wasylyk et al., 1993) . Studies in breast tumor cell-lines have implicated v-ets avian erythroblastosis virus E26 oncogene homolog-1, or Ets-1, in the progression of breast cancer (Gilles et al., 1997; Watabe et al., 1998) . Ets-1 is induced by, or required for the activation of, several genes involved in angiogenesis and in extracellular matrix (ECM) remodeling, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), urokinase plasminogen activator (uPA), matrix-metalloproteases (MMPs) and integrin b3 (Watabe et al., 1998; Iwasaka et al., 1996; Himelstein et al., 1998; Oda et al., 1999) . During early breast carcinogenesis, Ets-1 is upregulated together with MMP1 and MMP9 (Behrens et al., 2001) . Recently, Ets-1 expression was found to differ between tumors of ovarian cancer patients retrospectively selected for good or poor outcome (Davidson et al., 2001) . Here, we set out to assess the prognostic value of Ets-1 expression for breast cancer disease progression by quantitative Reverse Transcriptase Polymerase Chain Reaction (RT -PCR) in 123 sporadic breast cancer samples.
Tumor samples from patients with unilateral, operable breast cancer who underwent resection of their primary tumor between November 1987 and December 1997 were selected by the availability of frozen tissue in our tumor bank. The clinical data were retrospectively collected from the participating hospitals. Patients had no previous diagnosis of carcinoma, no distant metastases at time of diagnosis, and no evidence of disease within 1 month after primary surgery. Furthermore, patients receiving neo-adjuvant therapy or with carcinoma in situ only were excluded. Patients underwent modified radical mastectomy (n=98) or a breast saving procedure (n=25). The median follow-up time was 62 months (range 1.2 -164 months). The median age was 58.0 years (range 31 -88 years), and the median tumor size was 3.0 cm (range 0.8 -12.0 cm).
The primary breast cancer biopsies were pulverized in liquid nitrogen for routine estrogen (ER) and progesterone receptor (PgR) Ligand Binding Assay as recommended by the European Organization for Research and Treatment of Cancer (EORTC) (EORTC, 1980) . Aliquots of tissue powder were kept in liquid nitrogen until RNA isolation. Total RNA was isolated from 20 mg tissue powder using the RNeasy mini kit (Qiagen, Hilden, Germany) with on-column DNase I treatment. Quality of the RNA was checked by examining ribosomal RNA bands after agarose gelelectrophoresis, and by amplifying b-actin as a control (see below).
Reverse transcription was performed using the Reverse Transcription System (Promega Benelux B.V., Leiden, The Netherlands) according to the manufacturer's protocol. After annealing of random hexamers for 10 min at 208C, cDNA synthesis was performed for 60 min at 428C followed by an enzyme inactivation step for 5 min at 958C.
All PCR reactions were carried out using Taqman Universal PCR master mix (PE Applied Biosystems) with 500 nM of each primer and 100 nM of probe in a final volume of 25 ml. The Ets-1 forward primer was 5'-ccg tac gtc ccc cac tcc t-3', the reverse primer 5'-tgg gac atc tgc aca ttc ca-3', and the probe was 5'-FAM-cgt cga tct caa gcc gac tct cac cat-TAMRA-3'. These were designed intron-spanning using the Primer-Express software package version 1.5 (PE-Applied Biosystems) and based on the Ets-1 sequence with Genbank accession-number J04101. b-Actin was amplified using the Pre-Developed Assay Reagents Taqman RT -PCR assay from Perkin-Elmer (PE Applied Biosystems). Amplifications, with denaturation at 958C for 10 min, and 40 cycles of 15 s at 958C (melting) and 60 s at 588C (annealing and elongation), were performed on a ABI Prism 7700 Sequence detection system (PE Applied Biosystems). Quantification of unknown samples was performed using the breast cancer cellline MDA-MB361 as a calibrator.
Statistical analyses were carried out using SPSS 10.0.5 software (SPSS Benelux BV, Gorinchem, The Netherlands). To analyse interrelations between Ets-1 expression levels and various classical parameters, Spearman rank correlations were calculated. Relapsefree survival (RFS) time (defined as the time from primary surgery until the diagnosis of recurrent disease) and overall survival (OS) time (defined as the time between date of primary surgery and death by any cause) were used as follow-up parameters. Survival curves were generated using the method of Kaplan and Meier (1958) . Equality of survival distributions was tested using log-rank testing. The multivariate Cox proportional hazards model was used to assess the additive prognostic value of Ets-1 expression together with established factors that contributed to survival in univariate analysis (Cox, 1972) . Two-sided P-values below 0.05 were considered to be statistically significant. Cases with 472 months of follow-up were censored at 72 months, because of the rapidly declining number of patients thereafter.
In 47/123 (38.2%) of the cases, Ets-1 expression was undetectable after 40 rounds of amplification. The Ets-1 transcription factor/b-actin ratio ranged from 0.0084 to 0.224 (median 0.038) in the remaining 76 Ets-1 expressing breast cancer samples. Subsequent comparisons were made between Ets-1 expressing and nonexpressing tumor samples. No significant associations of Ets-1 expression with several established clinicopathological factors were found (Table 1) .
In univariate analysis, nodal status (P=0.0004), tumor size (P=0.0333) and Ets-1 expression (P=0.0011) had prognostic value for RFS (Table 2) . Patients whose primary tumors did not express Ets-1 (n=47) had a mean RFS time of 65.9 months (at a 85.4% 5-year RFS rate), whereas patients with tumors expressing Ets-1 (n=76) had a mean RFS time of 50.4 months (at a 55.2% 5-year RFS rate, Figure 1) . No unequivocal significant association of Ets-1 expression with OS was found (P=0.0535, data not shown).
In multivariate analysis with factors that were significantly prognostic in univariate analysis, i.e. nodal status and tumor size, Ets-1 expression retained its prognostic value for RFS (P=0.005, Table 2 ). The hazard ratio was 3.23 (95% CI, 1.43 -7.31).
Transcription factors regulate gene expression by binding to specific DNA sequences in the promoter/ enhancer regions of these genes. In this way, transcription factors control almost every developmental and homeostatic organismal process, including DNA replication and repair, cell growth and division, control of apoptosis and cellular differentiation (Benz, 1998) . Ets-1 was the first of the Ets-family of transcription factors to be described (Nunn et al., 1983; Watson et al., 1985) . Ets-1 controls the expression levels of a multitude of genes including other transcription factors, proteases, cell cycle regulating genes, apoptosis-related genes, cytokines and growth factors (reviewed in Sementchenko and Watson, 2000) .
The association of Ets-1 with poor prognosis in breast cancer that we describe here is at least in part Ets-1 independently predicts relapse in breast cancer PN Span et al attributable to the role of Ets-1 in regulating ECM remodeling (reviewed by Trojanowska, 2000) . Factors involved in ECM remodeling such as uPA and its inhibitor PAI-1 have established, strong prognostic value in breast cancer (Janicke et al., 2001; Look et al., 2002) . In breast tumor cell-lines, Ets-1 potentiates EGF-induced uPA expression (Watabe et al., 1998) . In concurrence with Davidson et al. (2001) , we found a significant correlation of Ets-1 expression levels with VEGF mRNA levels (Spearman R=0.359, P50.001) and, surprisingly, with plasminogen-activator-inhibitor-1 (PAI-1) protein levels (Spearman R=0.349, P50.001). However, no association with uPA protein levels was found (R=0.068, P=0.464, unpublished results). Originally, the specificity of Ets-mediated transcription regulation was thought to be mediated by the binding of Ets to GGAA/T core sequences in the promoter/enhancer sequence of a target gene. It has now become apparent, however, that Ets factors are able to bind to non-consensus sites. The target gene specificity and affinity of Ets binding to EBS is also controlled by the sequence context of the EBS in relation to other elements and binding to other transcription factors (reviewed in Sementchenko and Watson, 2000) . Whether PAI-1 expression is directly or indirectly controlled by Ets-1 in breast cancer, as suggested by the associations found in the present study, remains to be investigated.
In conclusion, here we describe a strong, independent association of Ets-1 with poor prognosis in breast cancer, which seems -at least in part -to be attributable to factors involved in angiogenesis (VEGF), and ECM remodeling (PAI-1). Figure 1 Relapse-free survival rates in breast cancer patients dichotomized by their expression of Ets-1 in the primary tumor. The number of patients at risk at a certain time point is given below the Figure. Patients with Ets-1 negative tumors exhibited a better prognosis (P=0.0011, log-rank testing)
